Table S1.Demographic and clinical characteristics of patients withacute HIV infection stratified by baseline CD4 count

Baseline CD4 >200cell/mm3 (n = 184) / Baseline CD4 ≤200cell/mm3 (n = 68) / p value
Age, median (IQR), years / 26 (23-30) / 27 (23-31) / 0.665
Male, n(%) / 183 (99.5) / 66 (97.1) / 0.013
Risk group for HIV transmission, n(%) / 0.628
Men who have sex with men / 174 (94.6) / 63 (92.6) / 0.568
Heterosexuals / 9 (4.9) / 5 (7.4) / 0.449
Injecting drug users / 1 (0.5) / 0(0) / 0.542
HBsAg positivity, n(%) / 11 (6.0) / 0(0) / 0.039
Anti-HBs positivity, n(%) / 94 (51.1) / 40 (58.8) / 0.298
Anti-HCV positivity, n(%) / 7 (3.8) / 2 (2.9) / 0.740
Anti-HAV IgG positivity, n(%) / 16/141 (11.3) / 10/49 (20.4) / 0.112
Baseline CD4, median (IQR), cells/mm3 / 356 (281-490) / 121 (68-174) / <0.001
Baseline PVL, median (IQR), log10 copies/ml / 5.6 (4.9-6.3) / 6.4 (5.9-7.0) / <0.001
Fiebig stage, n(%) / 0.070
Stage I / 3 (1.6) / 3 (4.4) / 0.199
Stage II / 2 (1.1) / 3 (4.4) / 0.093
Stage III / 24 (13.0) / 15 (22.1) / 0.079
Stage IV / 154 (83.7) / 47 (69.1) / 0.011
Stage V / 1 (0.5) / 0(0) / 0.542
CART, n(%) / 156 (84.8) / 58 (85.3) / 0.920
NRTI+NNRTI / 117 (63.6) / 47 (69.1) / 0.414
NRTI+PI / 19 (10.3) / 5 (7.4) / 0.475
NRTI+II / 20 (10.9) / 6 (8.8) / 0.636

Abbreviations: CART, combination antiretroviral therapy; HAV, hepatitis A virus; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; II, integrase inhibitor; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; nNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PVL, plasma HIV RNA load

Table S2.Clinical manifestations and physical findings of patients withacute HIV infection stratified by baseline CD4 count

Baseline CD4 >200cell/mm3 (n = 184) / Baseline CD4 ≤200cell/mm3 (n = 68) / p value
Clinical manifestations, n(%)
Fever / 139 (75.5) / 55 (80.9) / 0.371
Skin rash / 58 (31.5) / 20 (29.4) / 0.748
Pharyngitis / 95 (51.6) / 31 (45.6) / 0.394
Lymphadenopathy / 29 (15.8) / 5 (7.4) / 0.083
Myalgia / 53 (28.8) / 24 (35.3) / 0.321
Headache / 47 (25.5) / 12 (17.7) / 0.189
Diarrhea / 46 (25.0) / 17 (25.0) / 0.999
Arthralgia / 7 (3.8) / 2 (2.9) / 0.743
Cough / 35 (19.0) / 8 (11.8) / 0.174
Nausea / 33 (17.9) / 14 (20.6) / 0.631
Fatigue / 56 (30.4) / 33 (48.5) / 0.008
Vomiting / 16 (8.7) / 11 (16.2) / 0.088
Weight loss / 12 (6.5) / 18 (26.5) / <0.001
Night sweat / 1 (0.5) / 0(0) / 0.542
Genital ulcer / 9 (4.9) / 2 (2.9) / 0.501
Oral ulcer / 15 (8.2) / 10 (14.7) / 0.122
Aseptic meningitis / 12 (6.5) / 3 (4.4) / 0.530
Coinfection, n(%)
Syphilis / 49 (26.6) / 10 (14.7) / 0.047
Gonorrhea / 1 (0.5) / 1 (1.5) / 0.462
Chlamydia / 3 (1.6) / 1 (1.5) / 0.928
Condyloma / 2 (1.1) / 1(1.5) / 0.803
Candidiasis / 4(2.2) / 5(7.4) / 0.051
Cryptococcosis / 0 (0) / 1(1.5) / 0.101
Pneumocystosis / 1(0.5) / 6 (8.8) / <0.001
Salmonellosis / 0(0) / 1(1.5) / 0.101

Table S3. Initial laboratory values ofpatients with acute HIV infection stratified by baseline CD4 count

Baseline CD4 >200cell/mm3(n = 184) / Baseline CD4≤200 cell/mm3 (n = 68) / p value
WBC, cells/mm3 / 6155 (4790-7470) / 3830 (2470-5200) / <0.001
Hemoglobin, g/dL / 14.3 (13.6-15.2) / 13.3 (11.6-14.7) / <0.001
Platelet, x 103 cells/mm3 / 201 (158-236) / 143 (94-242) / 0.002
Lymphocyte, % / 36.1 (29.5-45.0) / 26.7 (18.5-39.0) / <0.001
Total bilirubin, mg/dL / 0.6 (0.4-0.9) / 0.7 (0.5-1.2) / 0.027
AST, U/L / 33 (23-76) / 54 (32-108) / 0.003
ALT, U/L / 38 (23-82) / 62 (31-109) / 0.032
BUN, mg/dL / 10.0 (8.5-14.0) / 12.0 (10.0-15.8) / 0.064
Creatinine, mg/dL / 0.8 (0.7-0.9) / 0.8 (0.7-0.9) / 0.817

*All values presented are median (IQR)

Abbreviations: ALT, alanineaminotransferase; AST, asparateaminotransferase; BUN, blood urea nitrogen; WBC, white blood cell count

1